Preoperative serum TMAO level is a new prognostic marker for colorectal cancer.
This study is aimed to determine whether trimethylamine-N-oxide (TMAO) is a predictor of prognosis of patients with colorectal cancer. Pretreatment TMAO serum levels were determined in 108 patients with colorectal cancer and 30 healthy controls. Median serum TMAO level was significantly higher in colorectal cancer patients than in healthy controls (p < 0.01). No correlation was observed between the disease-free survival and the type of chemotherapy regimen used, tumor location or lymphovascular invasion. Patients with high serum TMAO level had significantly shorter disease-free survival than patients with low serum TMAO level. Multivariate analysis showed that serum TMAO level and distant metastases were independent prognostic factors. Pretreatment serum TMAO level is identified as a new independent prognostic biomarker in patients with colorectal cancer.